MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "1-Methyl-4-phenylpyridinium (MPP+)"

  • 2022 International Congress

    Long non-coding RNAs in Parkinson’s disease: bringing back life to the grey matter?

    S. Acharya, A. Lumley, L. Zhang, V. Stopa, Y. Devaux (Strassen, Luxembourg)

    Objective: Our study aims to discover and delineate the role of novel long non-coding RNAs (lncRNAs) in Parkinson’s disease (PD). Background: LncRNAs have been widely…
  • 2022 International Congress

    Protective mechanism of melatonin via heat shock protein in the MPP+-induced in vitro Parkinson’s disease model

    YJ. Jung, E. Oh, A. Kim, H. Choi (Daejeon, Republic of Korea)

    Objective: The objective of this study was to investigate the protective properties of melatonin in an in vitro Parkinson’s disease (PD) model, especially focusing on…
  • 2022 International Congress

    Lack of Toll-like receptor 4 is associated with accumulation of alpha-synuclein in the midbrain Parkinson’s disease mice.

    C. Conte, G. Mariucci, R. Cafaro (Perugia, Italy)

    Objective: In this study we aimed to investigate the potential role of Toll-like receptor 4 (TLR4) in mediating both the dopaminergic neuron loss and alpha-synuclein (alpha-SYN)…
  • MDS Virtual Congress 2021

    Effects of fine particulate matter and cigarette smoking on MPTP-induced dopaminergic neuronal cell death: Implication for Parkinson’s disease

    YJ. Jung, H. Choi, E. Oh (Seoul, Republic of Korea)

    Objective: The objective of this study was to determine the potential neurotoxicity of fine particulate matter (FPM) and the neuroprotective properties of nicotine in the pathogenesis…
  • MDS Virtual Congress 2021

    The Role Imposed by The High-Mobility Group Box 1 (HMGB1) Protein in MPTP-Induced Zebrafish Model of Parkinson’s Disease

    K. Razali, WMY. Mohamed, N. Othman, MHM. Nasir, AA. Doolanea, J. Kumar (Kuantan, Malaysia)

    Objective: This study aims to investigate the role of HMGB1 protein in mediating neuroinflammatory-induced parkinsonian movement disorder of the MPTP-induced zebrafish model of Parkinson's disease…
  • MDS Virtual Congress 2021

    Technology use in Parkinson’s disease and parkinsonism: a multicenter survey in real-life Healthy East Lombardy Parkinson (HELP-)network

    A. Pilotto, S. Nocivelli, D. Alimenti, J. Melgari, M. Bianchi, V. de Giuli, A. Magherini, M. Rizzeti, F. Pisano, T. Di Monda, M. Gennuso, S. Gipponi, E. Cottini, A. Imarisio, S. Masciocchi, B. Bagni, E. Magni, M. Sessa, M. Turla, B. Ferraro, P. Trippa, A. Prelle, A. Ciccone, A. Padovani (Brescia, Italy)

    Objective: to evaluate the real-life use of internet and technological devices in parkinsonian patients Background: technology use is increasing in the ageing population but no…
  • MDS Virtual Congress 2020

    Abrogation of neuroinflammation and behavioural deficit by Chlorogenic acid and Tinosporia cordiofolia in MPTP-Induced Parkinsonian mice model via suppressing NF-κB pathway

    D. Singh, M. Singh (Allahabad, India)

    Objective: The current study was designed with the aim to investigate the anti-neuroinflammatory activity of chlorogenic acid (CGA) and ethanolic extract of Tinospora cordifolia (TPE)…
  • MDS Virtual Congress 2020

    4-Chlorokynurenine inhibits L-Dopa-induced dyskinesias in non-human parkinsonian primates

    T. Di Paolo, M. Bourque, R. Snodgrass (Quebec City, QC, Canada)

    Objective: This study investigated the antidyskinetic activity of 4-chlorokynurenine (AV-101) in parkinsonian monkeys with L-Dopa-induced dyskinesias. Background: The common treatment for Parkinson’s disease (PD) is L-Dopa…
  • MDS Virtual Congress 2020

    Perillyl alcohol restores mitochondrial dysfunction and abridge NLRP3 inflammasomes activation in in-vitro and in-vivo model of Parkinson’s disease

    P. Panda, S. Ahmed, V. Naidu (Kamrup, India)

    Objective: Parkinson's disease (PD) affects around 2-3% population of age greater than 65 and is the second most common neurogenerative disorder. The molecular mechanism underpinning…
  • MDS Virtual Congress 2020

    Activated microglia contribute to MPTP-induced impairment of cardiovascular function

    X. Liu, B. Wei, Q. Sun, Q. Bi, X. Shen, P. Shi (Hangzhou, China)

    Objective: To investigate the contribution of microglia in MPTP-induced loss of adrenergic neurons and impairment of cardiovascular function. Background: Parkinson’s disease (PD) is a neurodegenerative…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • AI-Powered Detection of Freezing of Gait Using Wearable Sensor Data in Patients with Parkinson’s Disease
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • #28970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley